NCT01147276

Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes

Study of the Effect of Vildagliptin on Glucagon Counterregulation Response During Hypoglycemia in Patients With Type 1 Diabetes

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Lund University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The study examines whether DPP-4 inhibition by vildagliptin affects the glucagon counterregulatory response to hypoglycemia in type 1 diabetes.

Detailed description

Vildagliptin (50 mg BID) or placebo is given as add-on to insulin treatment for four weeks in patients with type 1 diabetes. Then, a hypoglycemic clamp (2.5 mmol/l glucose) is undertaken with the determination of glucagon.

Conditions

• Diabetes
• Hypoglycemia

Interventions

Type	Name	Description
DRUG	Vildagliptin	Vildagliptin (50 mg BID) in four weeks

Timeline

• Start date: 2010-09-01
• Primary completion: 2011-09-01
• Completion: 2011-12-01
• First posted: 2010-06-22
• Last updated: 2012-09-25

Locations

1 site across 1 country: Sweden